Spans stroke, TBI, hypoxic and spinal injury; the broadest and least-developed of these pages
Neurological Injury
Neurological injury, the broad family that includes stroke, traumatic brain injury, oxygen-deprivation injury and spinal cord injury, is the least-developed area of psychedelic research on this site, and the one where the gap between hope and evidence is widest. As with brain injury generally, almost none of the work is about repairing damaged tissue; it is about the depression, anxiety, post-traumatic stress and lost functioning that follow, and, in animals, about whether psychedelics can nudge the brain’s own recovery. The single human result with real weight sits in the traumatic brain injury sub-topic (an uncontrolled magnesium-ibogaine study in veterans). Everywhere else the evidence is preclinical or very early, and ketamine’s main role is in acute intensive care, not psychedelic therapy.
This is an umbrella topic for acquired, structural damage to the nervous system: stroke, traumatic brain injury, oxygen-deprivation (hypoxic) injury and spinal cord injury. Its one sub-topic with a genuine human signal is traumatic brain injury, which has its own page.
2
As with brain injury generally, the research is about the after-effects (depression, anxiety, post-traumatic stress, lost functioning) and, in animal studies, about aiding the brain’s own recovery, not about repairing the injury. No psychedelic is shown to heal nervous-system damage.
3
The headline human result in the whole category is the uncontrolled magnesium-ibogaine study in blast-injured veterans, covered on the traumatic brain injury page. For stroke, hypoxic and spinal injury specifically, the evidence is essentially preclinical.
4
The mechanistic rationale (psychedelics promote neuroplasticity and reduce neuroinflammation) is appealing after an injury, and a few small, early trials are exploring adjacent conditions such as functional neurological disorder. But none of this is controlled human evidence of benefit for neurological injury.
5
Ketamine appears throughout this field mainly as an acute intensive-care drug (sedation, managing pressure in the skull, disorders of consciousness), which is not psychedelic therapy. No psychedelic is approved for any neurological injury.
By the numbers
19
Trials tracked
as of July 2026
29
Papers tracked
as of July 2026
1,370
Trial participants
as of July 2026
Research Landscape
What the 19 registered trials connected to Neurological Injury look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
How fast is Neurological Injury research growing?
Sourced
Registered trials by recorded study-start year. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (19 of 19 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
Sourced
Registry status of all 19 Neurological Injury trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which compounds carry the Neurological Injury research?
Sourced
Trials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.
What is Neurological Injury?
Neurological injury is a broad category covering acquired, structural damage to the nervous system: stroke (where blood supply to part of the brain is lost), traumatic brain injury, hypoxic or anoxic injury (where the brain is deprived of oxygen, for example after cardiac arrest), and spinal cord injury. Together these are among the largest causes of long-term disability in the world. Reviews of psychedelics for acquired brain injury set out both the scale of the problem and the early state of the science[1]Molecular Psychiatry, psychedelics for acquired brain injury review (2024).
The same distinction that governs the brain-injury research applies across this whole family, and it is the key to reading the page honestly: psychedelics are not shown to repair damaged neural tissue. What the research actually targets is twofold, the disabling psychiatric and functional after-effects of injury (depression, anxiety, post-traumatic stress, cognitive and motor problems), and, mostly in animal models, the brain’s own capacity for plastic recovery. Claims that a psychedelic "treats neurological injury" almost always mean one of those two things, not structural healing.
This is an umbrella page, and it is deliberately high-level, because the evidence is thin and concentrated. The one sub-area with a real human signal is traumatic brain injury, which has its own dedicated traumatic brain injury page; the closely related question of progressive, degenerative conditions is covered under neurocognitive disorders. Here we summarise the family as a whole and are candid about how little, beyond TBI, has actually been tested in people.
Current Treatments
Across these injuries the established approach is broadly similar: acute medical care to limit further damage (restoring blood flow in stroke, managing pressure and oxygen after brain injury, stabilising the spine), followed by intensive, long-term rehabilitation, physical, occupational, cognitive and speech therapy, that does the real work of recovery. There is no drug that reverses the injury itself, and rehabilitation, though effective, is slow and rarely complete.
The unmet need has two faces. The first is recovery itself: many people plateau with lasting deficits that no current treatment can shift. The second is the psychiatric burden, post-stroke depression, the anxiety and post-traumatic stress that follow brain injury, the demoralisation of life-changing disability, which is common, undertreated and a major driver of poor outcomes. Psychedelic research is aimed almost entirely at this second face, the mental-health after-effects, with the hope (so far mostly preclinical) that it might one day touch the first. Everything below is investigational.
Independent Research
Exploratory Research Report
This report summarises what Blossom’s database shows about psychedelics and neurological injury, the broad family that includes stroke, traumatic brain injury, oxygen-deprivation injury and spinal cord injury. It is the least-developed topic in this collection, and an honest account is mostly an account of absence: a great deal of mechanistic promise, one striking but uncontrolled human result confined to traumatic brain injury, and almost no controlled human evidence anywhere else.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for, or shown to repair, any neurological injury. One of the drugs discussed, ibogaine, can cause fatal heart-rhythm disturbances and is mostly used in unregulated overseas settings. Established care, acute medical treatment plus long-term rehabilitation, and evidence-based treatment of the depression and anxiety that follow injury, is the foundation and should not be set aside in favour of experimental options. If you or someone you care for is recovering from a neurological injury, please work with the clinical team.
A word on scope and numbers. Blossom tracks only a few dozen papers and trials here, and they are unusually mixed: mechanism reviews, animal studies, ketamine used as an intensive-care anaesthetic, and work that really belongs to the traumatic brain injury sub-topic. The amount of controlled human evidence testing a psychedelic as a treatment for neurological injury is, in practice, close to zero. Read the counts as breadth of interest in a young field, not as depth of proof.
One umbrella, very uneven evidence
The first thing to understand is that "neurological injury" is not one evidence base but several, of wildly different maturity. Traumatic brain injury has attracted real human research and has its own page. Stroke, the other huge category, has essentially no psychedelic clinical trials, only preclinical work and the general interest in post-stroke depression. Hypoxic and spinal cord injuries have less still. So statements about "psychedelics for neurological injury" almost always rest on TBI data or on animal studies, and stretching them across the whole family is exactly the kind of overreach this page exists to flag.
The unifying idea, and the honest boundary, is the same as on the brain-injury page: this research is about the after-effects of injury and about the brain’s plastic recovery, not about repairing damaged tissue. A stroke kills neurons; a psychedelic does not bring them back. What it might plausibly do, on current thinking, is ease the depression and anxiety that follow, and perhaps support the rehabilitation process by enhancing plasticity. Both are hypotheses worth testing, and neither is established.
The one human signal, and where it lives
The only result in this family with real human weight is the magnesium-ibogaine work in veterans, and it belongs to traumatic brain injury specifically. An uncontrolled study reported large improvements in PTSD, depression, anxiety and functioning in special-operations veterans with blast-related TBI[1]Nature Medicine, magnesium-ibogaine veterans TBI (MISTIC, 2024). It is genuinely striking, and genuinely limited: observational, self-selected, conducted at an overseas clinic, and reliant on a drug that can stop the heart. The full account and its caveats are on the traumatic brain injury page, because it would be misleading to present a single uncontrolled TBI study as evidence for "neurological injury" in general.
There are fainter echoes elsewhere, such as a case series of iboga microdosing in post-concussive and hypoxic brain injury[2]Front Pharmacol, iboga microdosing post-concussive and hypoxic injury case series (2026) and observational reports of psilocybin retreats improving mental health in veterans with injury histories[3]Front Psychiatry, psilocybin retreat in veterans with TBI history (2025). These are worth knowing and easy to over-read: they are uncontrolled, self-selected and small. They point toward trials; they do not stand in for them.
The mechanistic promise, and its limits
The reason serious researchers take this field seriously despite the thin clinical evidence is the biology. Classic psychedelics reliably promote neuroplasticity, the growth and rewiring of neural connections, and reduce neuroinflammation, and reviews of psychedelics for acquired brain injury lay out in detail why those effects are attractive in the aftermath of an injury[4]Molecular Psychiatry, psychedelics for acquired brain injury review (2024), when the brain is trying to reorganise around damage. In animal models of brain injury, these effects translate into measurable improvements.
The limit is the gap between a mouse and a person. Many interventions improve recovery in animal injury models and then fail in human trials, because the human brain, the injuries, and the outcomes that matter are all more complex. So the neuroplasticity story is a strong reason to run trials, not a substitute for their results. The most concrete human steps so far are in adjacent conditions, early trials of psilocybin-assisted approaches in functional neurological disorder, for instance, rather than in the core injuries of stroke or spinal damage.
Ketamine: an acute-care drug that is mostly off-topic
A large share of the "psychedelic" research that appears under neurological injury is really about ketamine in intensive care, and it is worth separating out. Ketamine is a valuable acute anaesthetic in severe brain injury because it works fast and does not suppress breathing, and it is studied for managing intracranial pressure and even for its physiological effects and outcomes after brain injury[5]J Trauma Inj, ketamine after brain injury outcomes retrospective (2023), as well as, experimentally, for waking patients from disorders of consciousness. None of that is psychedelic therapy; it is mainstream neurocritical care that happens to use the same molecule.
The genuinely on-topic ketamine question, using its rapid antidepressant effect for the mood consequences of injury such as post-stroke depression, is real but early, with only small trials so far. Keeping these two ketamines apart matters: conflating the well-established intensive-care use with the speculative sequelae-treatment use would make the evidence base look far stronger than it is.
Reading this honestly
So where does neurological injury sit? It is the widest and emptiest of these pages: a family of devastating, common conditions, a compelling biological rationale, and almost no controlled human evidence that psychedelics help any of them. The one striking human result is confined to traumatic brain injury, is uncontrolled, and depends on a dangerous drug. Everywhere else, stroke, hypoxic injury, spinal cord injury, the case rests on animal studies and hope. Reviewers in the area consistently frame it as promising but preliminary[6]Front Neurol, psychedelics for brain injury mini-review (2021), and that is the right note. For people living with the aftermath of a neurological injury, the truthful message is that psychedelics are an active and genuinely interesting area of research, especially for the psychiatric after-effects, and that they are not, today, a treatment for the injury or a substitute for the rehabilitation and mental-health care that remain the real foundations of recovery.
Blossom Pro Research Report
Upgrade to Blossom Pro to read this report and the structured analysis layers.
The only compound with a human signal in this family, and it is concentrated in traumatic brain injury: an uncontrolled magnesium-ibogaine study in blast-injured veterans (see the TBI page). It targets the psychiatric after-effects, not the injury, and ibogaine carries a fatal cardiac-arrhythmia risk. No evidence in stroke, hypoxic or spinal injury.
No controlled human evidence in neurological injury. The appeal is mechanistic (neuroplasticity, reduced inflammation in animal models) plus early observational data in veterans and small trials in adjacent conditions such as functional neurological disorder. A plausible hypothesis, not a demonstrated treatment.
Mostly a separate, acute-care story: ketamine is used in the intensive-care management of severe brain injury (sedation, intracranial pressure, disorders of consciousness), which is not psychedelic therapy. Its use for the depression that follows injury (e.g. post-stroke depression) is only beginning to be trialled.
The only compound with a human signal in this family, and it is concentrated in traumatic brain injury: an uncontrolled magnesium-ibogaine study in blast-injured veterans (see the TBI page). It targets the psychiatric after-effects, not the injury, and ibogaine carries a fatal cardiac-arrhythmia risk. No evidence in stroke, hypoxic or spinal injury.
No controlled human evidence in neurological injury. The appeal is mechanistic (neuroplasticity, reduced inflammation in animal models) plus early observational data in veterans and small trials in adjacent conditions such as functional neurological disorder. A plausible hypothesis, not a demonstrated treatment.
Mostly a separate, acute-care story: ketamine is used in the intensive-care management of severe brain injury (sedation, intracranial pressure, disorders of consciousness), which is not psychedelic therapy. Its use for the depression that follows injury (e.g. post-stroke depression) is only beginning to be trialled.
Small MagnitudeLow EvidenceLow Consistency
Published research
4
linked papers
0
clinical papers
1
syntheses
Latest linked paper 2023
Registered research
11 registered trials
4 recruiting/opening
696 combined reported enrollment
Highest Phase IV
Ibogaine and Neurological Injury
Ibogaine is the only compound that has produced a striking human result anywhere in this family, and that result is specific to traumatic brain injury, not neurological injury broadly. An uncontrolled study of magnesium-ibogaine in special-operations veterans with blast-related TBI reported large improvements in PTSD, depression, anxiety and functioning[1]Nature Medicine, magnesium-ibogaine veterans TBI (MISTIC, 2024). Because it belongs to the TBI sub-topic, the detail, and the important caveats about its observational design and ibogaine’s cardiac danger, live on the traumatic brain injury page.
Beyond TBI, ibogaine in neurological injury is barely studied. There is early, anecdotal interest, such as a case series of an iboga microdosing protocol in post-concussive and hypoxic brain injury[2]Front Pharmacol, iboga microdosing post-concussive and hypoxic injury case series (2026), but this is the weakest kind of evidence and, given ibogaine’s capacity to cause fatal heart-rhythm disturbances, not a basis for use. For stroke and spinal injury specifically, there is essentially nothing.
Psilocybin is the compound most associated with the hopeful, recovery-focused side of this field, and that hope is mostly mechanistic. Classic psychedelics promote neuroplasticity and reduce neuroinflammation in the laboratory, and reviews argue these properties could in principle support recovery after an acquired brain injury[1]Molecular Psychiatry, psychedelics for acquired brain injury review (2024). The human data remain observational and indirect: for example, veterans with a history of brain injury who attended psilocybin retreats reported better mental health and showed normalised resting brain activity[2]Front Psychiatry, psilocybin retreat in veterans with TBI history (2025).
The most concrete movement is in adjacent neurological conditions rather than in stroke or spinal injury: early trials are testing psilocybin-assisted approaches in functional neurological disorder, and a first study in persistent post-concussive symptoms is recruiting (on the TBI page). For neurological injury as a whole, psilocybin is a mechanistically attractive idea with, as yet, no controlled human evidence of benefit, and any effect is far more likely to be on mood and functioning than on the injury itself.
Ketamine is everywhere in neurological-injury medicine, but mostly in a role unrelated to psychedelic therapy. As a fast-acting anaesthetic that preserves breathing and blood pressure, it is widely used in the acute, intensive-care management of severe brain injury, where analyses look at its effects on physiology such as intracranial pressure and on outcomes[1]J Trauma Inj, ketamine after brain injury outcomes retrospective (2023), and it is even being studied as a way to improve consciousness in patients with post-comatose disorders of consciousness. This is mainstream neurocritical care.
Separately, and much more tentatively, ketamine’s rapid antidepressant effect is being explored for the mood consequences of injury, including small trials in post-stroke depression. That fits the wider pattern on this page: a plausible treatment for the psychiatric after-effects, still early and unproven. The two uses should not be conflated, the acute-care role is established; the psychedelic-style, sequelae-focused role is exploratory.
The realistic near-term outlook is that progress in this umbrella will come almost entirely through its sub-areas, above all traumatic brain injury, rather than through "neurological injury" as a single target. The momentum from the magnesium-ibogaine work, a recruiting psilocybin trial in post-concussive symptoms, and ketamine trials in injury-related depression are the concrete steps, now joined by a $50 million Texas state programme in which UT Austin and Baylor College of Medicine will study ibogaine for traumatic brain injury in veterans; the broader brain-injury literature continues to make the mechanistic case[1]Front Neurol, psychedelics for brain injury mini-review (2021) for stroke and other injuries, but largely from animal data.
For stroke, hypoxic injury and spinal cord injury specifically, the honest outlook is that controlled human research has barely begun, and that the exciting preclinical findings about neuroplasticity have not yet been put to a real clinical test. The most valuable developments would be unglamorous: properly controlled trials targeting well-defined after-effects (post-stroke depression, for instance) in clearly defined injury populations. Until those exist, this remains a field of strong rationale and weak evidence, and the gap should be stated plainly rather than papered over.
Industrial Landscape
The activity in this space is fragmented and early, and clusters around the sub-areas rather than the umbrella. The most organised effort is in traumatic brain injury, driven by veteran-focused researchers and advocates; elsewhere, interest comes from academic neuroscientists drawn by the neuroplasticity story and from rehabilitation researchers looking for anything that might improve recovery. There is little commercial development aimed specifically at stroke or spinal injury, partly because the evidence is so preliminary.
For an honest broker, the risk here is a particular kind of overreach: the leap from genuinely exciting laboratory findings about neuroplasticity to the implication that psychedelics can help people recover from strokes or repair spinal injuries. Nothing in the human evidence supports that yet. The responsible message is to welcome the mechanistic research and the early TBI signal, to push for the controlled trials that would test the broader promise, and to be clear with patients and families that, for neurological injury beyond a single uncontrolled study in TBI, this is hope grounded in biology, not treatment grounded in evidence.
Blossom Pro Structured Analysis
Unlock compound evidence, clinical outlook, and stakeholder analysis.